NASDAQ:BIOL - BIOLASE Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BIOLASE Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.77 0.00 (0.00 %) (As of 02/23/2020 04:00 PM ET) Add Compare Today's Range$0.75Now: $0.77▼$0.8250-Day Range$0.57MA: $0.67▼$0.8752-Week Range$0.43Now: $0.77▼$2.87Volume106,131 shsAverage Volume152,064 shsMarket Capitalization$23.93 millionP/E RatioN/ADividend YieldN/ABeta2.19 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BIOLASE, Inc, a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the worldwide. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; and diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Dental equipment & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BIOL Previous SymbolNASDAQ:BLTI CUSIPN/A CIK811240 Webhttp://www.biolase.com/ Phone949-361-1200Debt Debt-to-Equity Ratio3.51 Current Ratio1.66 Quick Ratio0.84Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$46.15 million Price / Sales0.52 Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book1.43Profitability EPS (Most Recent Fiscal Year)($0.85) Net Income$-21,520,000.00 Net Margins-52.13% Return on Equity-313.64% Return on Assets-49.04%Miscellaneous Employees190 Outstanding Shares30,950,000Market Cap$23.93 million Next Earnings Date3/3/2020 (Estimated) OptionableNot Optionable Receive BIOL News and Ratings via Email Sign-up to receive the latest news and ratings for BIOL and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:BIOL Rates by TradingView BIOLASE (NASDAQ:BIOL) Frequently Asked Questions What is BIOLASE's stock symbol? BIOLASE trades on the NASDAQ under the ticker symbol "BIOL." When did BIOLASE's stock split? How did BIOLASE's stock split work? BIOLASE's stock reverse split on Friday, May 11th 2018. The 1-5 reverse split was announced on Thursday, May 10th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 10th 2018. An investor that had 100 shares of BIOLASE stock prior to the reverse split would have 20 shares after the split. How were BIOLASE's earnings last quarter? BIOLASE Inc (NASDAQ:BIOL) released its quarterly earnings data on Wednesday, November, 6th. The medical technology company reported ($0.12) EPS for the quarter, beating the Zacks' consensus estimate of ($0.25) by $0.13. The medical technology company earned $8.65 million during the quarter. BIOLASE had a negative return on equity of 313.64% and a negative net margin of 52.13%. View BIOLASE's Earnings History. When is BIOLASE's next earnings date? BIOLASE is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for BIOLASE. What price target have analysts set for BIOL? 4 brokers have issued 1-year price targets for BIOLASE's shares. Their forecasts range from $2.00 to $3.00. On average, they anticipate BIOLASE's share price to reach $2.50 in the next twelve months. This suggests a possible upside of 223.4% from the stock's current price. View Analyst Price Targets for BIOLASE. What is the consensus analysts' recommendation for BIOLASE? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIOLASE. Has BIOLASE been receiving favorable news coverage? News headlines about BIOL stock have been trending very negative this week, according to InfoTrie. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. BIOLASE earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news coverage about the medical technology company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the next several days. View News Stories for BIOLASE. Who are some of BIOLASE's key competitors? Some companies that are related to BIOLASE include Straumann (SAUHF), DENTSPLY SIRONA (XRAY), Sartorius (SARTF), SmileDirectClub (SDC), Biomerica (BMRA) and Remedent (REMI). What other stocks do shareholders of BIOLASE own? Based on aggregate information from My MarketBeat watchlists, some companies that other BIOLASE investors own include Himax Technologies (HIMX), Accelerate Diagnostics (AXDX), Magnachip Semiconductor (MX), Fluidigm (FLDM), NovaBay Pharmaceuticals (NBY), Vuzix (VUZI), Athersys (ATHX), Allena Pharmaceuticals (ALNA), Biocept (BIOC) and CTI BioPharma (CTIC). Who are BIOLASE's key executives? BIOLASE's management team includes the folowing people: Mr. Todd A. Norbe, Pres, CEO & Director (Age 52)Mr. John R. Beaver, Exec. VP & CFO (Age 58)Mr. Richard R. Whipp, VP of Operations (Age 67)Mr. William E. Brown Jr., VP of Bus. Devel. (Age 71)Mr. Daniel Merkin, National Sales Director (Age 46) Who are BIOLASE's major shareholders? BIOLASE's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Archon Capital Management LLC (8.65%) and Perkins Capital Management Inc. (4.26%). Company insiders that own BIOLASE stock include Garrett Sato, John R Beaver, Jonathan T Md Lord, Larry N Feinberg and Todd Norbe. View Institutional Ownership Trends for BIOLASE. Which institutional investors are buying BIOLASE stock? BIOL stock was purchased by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc. and Archon Capital Management LLC. Company insiders that have bought BIOLASE stock in the last two years include Garrett Sato, John R Beaver, Jonathan T Md Lord, Larry N Feinberg and Todd Norbe. View Insider Buying and Selling for BIOLASE. How do I buy shares of BIOLASE? Shares of BIOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is BIOLASE's stock price today? One share of BIOL stock can currently be purchased for approximately $0.77. How big of a company is BIOLASE? BIOLASE has a market capitalization of $23.93 million and generates $46.15 million in revenue each year. The medical technology company earns $-21,520,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis. BIOLASE employs 190 workers across the globe.View Additional Information About BIOLASE. What is BIOLASE's official website? The official website for BIOLASE is http://www.biolase.com/. How can I contact BIOLASE? BIOLASE's mailing address is 4 Cromwell, Irvine CA, 92618. The medical technology company can be reached via phone at 949-361-1200 or via email at [email protected] MarketBeat Community Rating for BIOLASE (NASDAQ BIOL)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 259 (Vote Outperform)Underperform Votes: 257 (Vote Underperform)Total Votes: 516MarketBeat's community ratings are surveys of what our community members think about BIOLASE and other stocks. Vote "Outperform" if you believe BIOL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/23/2020 by MarketBeat.com StaffFeatured Article: What is a Call Option?
